Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Generation of a microRNA-Regulated Oncolytic Coxsackievirus B3.

Dieringer B. et al, (2022), Methods Mol Biol, 2521, 259 - 282

Coxsackievirus B3-Its Potential as an Oncolytic Virus.

Geisler A. et al, (2021), Viruses, 13

Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Fisher K. et al, (2021), Cancers (Basel), 13

MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells

Pryshliak M. et al, (2020), FEBS Letters, 594, 763 - 775

New postmortem diagnostic biomarker for myocardial infarction: ischemia modified albumin

Yağmur F. et al, (2019), Australian Journal of Forensic Sciences, 51, 191 - 200

Investigation of ischemia modified albumin, oxidant and antioxidant markers in acute myocardial infarction

Hazini A. et al, (2015), Postepy w Kardiologii Interwencyjnej, 11, 298 - 303

Prevention of cyclophosphamide-induced hemorrhagic cystitis by resveratrol: a comparative experimental study with mesna

Keles I. et al, (2014), International Urology and Nephrology, 46, 2301 - 2310